STOCK TITAN
  1. Home
  2. Financials
  3. XTLB

Xtl Biopharmaceu Financials

XTLB
Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE June

This page shows Xtl Biopharmaceu (XTLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI XTLB FY2024

Tiny commercial revenue and externally funded balance-sheet expansion show a business still financed by capital raises, not customers.

FY2024 total assets jumped to $8.6M from $2.4M in FY2023. But current assets shrank and the current ratio dropped below 1.0x, so the company became larger on paper while near-term liquidity tightened as more assets sat in less spendable forms such as goodwill.

With just $451K of revenue against $1.6M of operating cash outflow, FY2024 still looks like an externally financed operating model rather than a self-supporting commercial one. The financing inflow of $1.4M alongside higher share count shows cash needs were met mainly through new capital, not through internal cash generation.

The very low debt-to-equity ratio can make leverage look mild, but cash was only $371K against $2.2M of current liabilities. That shifts the real constraint to short-term liquidity: the issue is covering upcoming obligations, not servicing a heavy long-term debt load.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating Xtl Biopharmaceu's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$451K
YoY+0.0%

Xtl Biopharmaceu generated $451K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.

EBITDA
N/A
Net Income
N/A
EPS (Diluted)
$-0.00

Xtl Biopharmaceu earned $-0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$1.1M
YoY+35.5%

Xtl Biopharmaceu generated -$1.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 35.5% from the prior year.

Cash & Debt
$76K
YoY-79.5%
5Y CAGR-53.9%
10Y CAGR-32.4%

Xtl Biopharmaceu held $76K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
946M
YoY+7.4%
5Y CAGR+13.0%

Xtl Biopharmaceu had 946M shares outstanding in fiscal year 2025. This represents an increase of 7.4% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
$54K
YoY+0.0%
5Y CAGR+122.1%
10Y CAGR+39.0%

Xtl Biopharmaceu invested $54K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

XTLB Income Statement

Metric Q2'25 Q1'25 Q2'24 Q2'23 Q4'22 Q2'22 Q4'21 Q2'21
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A N/A N/A N/A N/A
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense N/A N/A N/A N/A -$83K N/A -$847K N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income N/A N/A N/A N/A -$285K N/A -$1.1M N/A
EPS (Diluted) N/A N/A N/A N/A N/A N/A N/A N/A

XTLB Balance Sheet

Metric Q2'25 Q1'25 Q2'24 Q2'23 Q4'22 Q2'22 Q4'21 Q2'21
Total Assets $8.6M+46.4% $5.8M+140.8% $2.4M-42.0% $4.2M-27.3% $5.8M-13.0% $6.6M-4.8% $7.0M+6.9% $6.5M
Current Assets $1.3M N/A $2.0M-46.2% $3.8M-29.2% $5.4M-13.8% $6.2M-5.1% $6.6M+7.4% $6.1M
Cash & Equivalents $371K N/A $1.4M-33.1% $2.1M-10.7% $2.3M-21.0% $3.0M+1.7% $2.9M-19.6% $3.6M
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill $3.2M0.0% $3.2M N/A N/A N/A N/A N/A N/A
Total Liabilities $3.1M-46.7% $5.8M+2735.9% $206K+10.2% $187K-3.6% $194K-84.9% $1.3M-65.0% $3.7M+27.0% $2.9M
Current Liabilities $2.2M N/A $206K N/A N/A N/A N/A N/A
Long-Term Debt $138K N/A N/A N/A N/A N/A N/A N/A
Total Equity $5.4M $0-100.0% $2.2M-44.5% $4.0M-28.1% $5.6M+4.3% $5.3M+62.5% $3.3M-9.1% $3.6M
Retained Earnings -$159.0M N/A -$158.2M-1.1% -$156.5M-1.0% -$154.9M+0.1% -$155.1M+0.8% -$156.4M-0.5% -$155.6M

XTLB Cash Flow Statement

Metric Q2'25 Q1'25 Q2'24 Q2'23 Q4'22 Q2'22 Q4'21 Q2'21
Operating Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

XTLB Financial Ratios

Metric Q2'25 Q1'25 Q2'24 Q2'23 Q4'22 Q2'22 Q4'21 Q2'21
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A -5.1% N/A -35.0% N/A
Return on Assets N/A N/A N/A N/A -5.0% N/A -16.5% N/A
Current Ratio 0.61 N/A 9.93 N/A N/A N/A N/A N/A
Debt-to-Equity 0.03 N/A 0.09+0.0 0.05+0.0 0.03-0.2 0.24-0.9 1.12+0.3 0.80
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$254K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Immuron Ltd IMRN
$9.0M
Leap Therapeutic LPTX
$116.1M
APOLLOMICS INC APLM
$40.0M
Phio Pharmaceuticals Corp PHIO
$12.1M
Biorestorative Therapies Inc BRTX
$7.4M

Frequently Asked Questions

Xtl Biopharmaceu (XTLB) reported $451K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Xtl Biopharmaceu (XTLB) revenue grew by 0% year-over-year, from $451K to $451K in fiscal year 2025.

Xtl Biopharmaceu (XTLB) reported diluted earnings per share of $-0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Xtl Biopharmaceu (XTLB) generated -$1.1M in free cash flow during fiscal year 2025. This represents a 35.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Xtl Biopharmaceu (XTLB) generated -$1.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Xtl Biopharmaceu (XTLB) had $166K in total assets as of fiscal year 2025, including both current and long-term assets.

Xtl Biopharmaceu (XTLB) invested $54K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Xtl Biopharmaceu (XTLB) had 946M shares outstanding as of fiscal year 2025.

Based on fiscal year 2025 data, Xtl Biopharmaceu (XTLB) had $76K in cash against an annual operating cash burn of $1.0M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Xtl Biopharmaceu (XTLB) has negative shareholder equity of -$254K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top